Eloralintide
ENLIGHTEN-3
Eli Lilly · Phase 3 · Recruiting · Enrollment 800
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Eloralintide (YSA1) | Obesity or overweight | n/r | 76 | n/r | n/r |
| Placebo (YSA1) | Obesity or overweight | n/r | 76 | n/r | n/r |
| Eloralintide (YSA2) | Obesity or overweight | n/r | 76 | n/r | n/r |
| Placebo (YSA2) | Obesity or overweight | n/r | 76 | n/r | n/r |